Dear consultee/commentator,

Single Technology Appraisal

Ixabepilone for locally advanced or metastatic breast cancer

The manufacturer recently received a negative CHMP opinion for Ixabepilone for locally advanced or metastatic breast cancer. Consequently this appraisal will be suspended until we receive an update from the manufacturer on the status of regulatory approval.

You will be updated in due course.

Yours sincerely,